Cipla Focuses its China Investment, Emphasizes Biosimilars
05:26 EDT 14 Aug 2012 | ChinaBio Today
Cipla, the Indian generic drug maker, pulled $72 million out of its 49% investment in China’s Desano Holdings, and then put between $20 million and $25 million into each of three Desano subsidiaries in which Cipla is already invested. The co..
Original Article: Cipla Focuses its China Investment, Emphasizes Biosimilars
More From BioPortfolio on "Cipla Focuses its China Investment, Emphasizes Biosimilars"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
